| J0897 | Injection, denosumab, 1 mg | 24,420 | $20 | $439.6K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11,200 | $30 | $380.8K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 33,810 | $10 | $270.5K |
| J3262 | Injection, tocilizumab, 1 mg | 39,760 | $10 | $198.8K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 32,200 | $1 | $128.8K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 11,300 | $10 | $124.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,160 | $100 | $113.5K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4,160 | $30 | $108.2K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 860 | $70 | $60.1K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 900 | $60 | $53.2K |